Immunotherapy: Towards on early non-small cell lung cancer

VernacularTitle: 迈向早期非小细胞肺癌的免疫治疗
Author: Mei-qi SHI ¹ ; Ru TAO ¹
Author Information

1. Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu, China
Publication Type:Journal Article
Keywords: early resectable NSCLC; adjuvant immunotherapy; neo-adjuvant immunotherapy
From: Journal of Medical Postgraduates 2019;32(8):785-790
CountryChina
Language:Chinese
Abstract: Surgery is the standard treatment for early resectable non-small cell lung cancer (NSCLC), but the recurrence rate is high. There is no effective cure for this. Immunological checkpoint inhibitors have altered the therapeutic model of patients with advanced gene therapy for advanced NSCLC, presenting new hope for early immunotherapy of NSCLC. Immunological checkpoint inhibitors have altered the therapeutic model of patients with driving gene-negative NSCLC patients, presenting new hope for early immunotherapy of NSCLC. Based on the analysis of the status of early NSCLC adjuvant therapy, the clinical study of immunological checkpoint inhibitors as a new adjuvant/adjuvant therapy in early operable NSCLC was explored in this paper.